- Home
- FSBC vs KALV Comparison
FSBC vs KALV Comparison
Compare FSBC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSBC | KALV |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.1M | 757.7M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FSBC | KALV |
|---|---|---|
| Price | $36.35 | $16.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $40.75 | $30.00 |
| AVG Volume (30 Days) | 65.3K | ★ 709.7K |
| Earning Date | 04-28-2026 | 04-13-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 28.32 | N/A |
| EPS | ★ 2.90 | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $29.27 | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | $12.68 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $22.22 | $9.83 |
| 52 Week High | $42.26 | $19.00 |
Technical Indicators
Market Signals| Indicator | FSBC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 29.75 | 56.12 |
| Support Level | $36.20 | $14.59 |
| Resistance Level | $38.25 | $19.00 |
| Average True Range (ATR) | 1.36 | 0.92 |
| MACD | -0.39 | 0.15 |
| Stochastic Oscillator | 12.25 | 49.20 |
Price Performance
Historical ComparisonAbout FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.